Global Mycoplasma Testing Market will grow at highest pace owing to increasing R&D activities in pharmaceutical industry

 

Global Mycoplasma Testing Marke

Mycoplasma testing involves screening of cell culture samples for the presence of mycoplasma contamination. Mycoplasmas are the smallest self-replicating prokaryotes, lack cell walls and known to cause chronic or degenerative diseases in animals and humans respectively. Mycoplasma testing performed to avoid contamination during production of biopharmaceuticals, helps maintaining high quality standards.

 The Global Mycoplasma Testing Market is estimated to be valued at US$ 997.8 Mn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Global Mycoplasma Testing market are Charles River Laboratories International, Merck KGaA, Lonza Group Ltd, Roche Diagnostics, Thermo Fisher Scientific, Merck, InvivoGen, Creative Bioarray. Increased adoption of mycoplasma testing in cell culture screening and growing R&D expenditure in biopharmaceutical industry are major factors supplementing growth of the market. Advent of new technologies such as digital PCR, next generation sequencing are accelerating market expansion by enabling early detection of mycoplasma contamination in cell culture samples.

Market trends

The Global Mycoplasma Testing Market Size is witnessing increased demand for multi-parameter testing kits owing to advantages such as simultaneous detection of multiple mycoplasma species. Growing popularity of PCR-based detection methods such as qPCR attributed to high sensitivity, specificity and rapid turnaround time. However, high cost of advanced detection platforms poses major challenge.

Market Opportunities

Emerging economies in Asia Pacific provide lucrative growth opportunities, driven by expanding biopharmaceutical industry and increasing healthcare spending. Novel techniques such as culture-based microfluidic lab-on-a-chip systems and humanized cell lines are expected to gain momentum over forecast period.

Impact of COVID-19 on Global Mycoplasma Testing Market Growth

The COVID-19 pandemic has significantly impacted the growth of the global mycoplasma testing market. In the pre-COVID era, the market was growing at a healthy rate driven by increasing research activities in the biopharmaceutical industry and rising outsourcing of testing. However, the outbreak of the virus disrupted supply chains and stalled research activities globally.

Various lockdown restrictions imposed across countries led to the temporary closure of multiple research laboratories, delaying ongoing research projects. It adversely affected the demand for mycoplasma testing products. The cancellation and postponement of non-COVID clinical trials also impacted the market negatively. With researchers focusing more on developing vaccines and therapeutics for COVID-19, routine testing needs saw a decline.

However, with vaccination drives and easing lockdowns post-2020, the market is gradually recovering. The resumption of research projects and restarting of clinical trials are fuelling demand. Moreover, the establishment of multiple COVID-19 testing facilities increased the adoption of mycoplasma detection kits. The growing focus of companies on ensuring biosafety and quality of biopharmaceutical products will further support market growth in the coming years. Market players are also focusing on developing novel detection technologies and kits with improved accuracy and shorter turnaround time to meet current challenges.

Regions with Highest Market Concentration in Terms of Value

North America dominated the global mycoplasma testing market in terms of value in 2024, owing to the presence of leading biopharmaceutical companies and contract manufacturing organizations in the region. Strong government funding for research, high rate of drug development, and stringent regulations for cell line and biosafety testing further contributed to the regional market growth. Europe held the second largest share due to the expanding biotechnology industry and increasing outsourcing activities in countries like Germany, UK, and France.

Fastest Growing Region in the Global Mycoplasma Testing Market

Asia Pacific is expected to witness the fastest growth during the forecast period. This can be attributed to rising investments by pharmaceutical giants in the region, growing biologics manufacturing, and strengthening research infrastructure across India and China. In addition, improving regulations, low manufacturing costs, and increasing product outsourcing to Asia are supporting the regional market.

Get more insights on This Topic- Global Mycoplasma Testing Market